Skip to main content
SpringerLink
Log in

Compounds Acting on the Parathyroid Calcium Receptor as Novel Therapies for Hyperparathyroidism or Osteoporosis

  • Chapter
Calcium-Sensing Receptor

Part of the book series: Endocrine updates ((ENDO,volume 19))

Abstract

Parathyroid hormone (PTH) is the key endocrine factor in systemic Ca2+ homeostasis and many of its actions in this capacity involve moving Ca2+ between bone and blood. Its actions on bone are complex and PHT can stimulate net bone loss or formation depending upon temporal changes in the levels of circulating hormone. Chronically elevated levels of plasma PTH, as occurs in primary or secondary hyperparathyroidism, stimulate osteoclastic bone resorption resulting in net bone loss and osteopenia. In contrast, PHT stimulates new bone formation when plasma levels of PHT are elevated only briefly. The administration of exogenous PHT to cause a brief rise in plasma levels of PHT is effective in treating osteoporosis. There are no pharmaceuticals, however, that effectively lower the chronically elevated levels of PHT in hyperparathyroidism. It is conceivable that drugs which either increase or decrease the secretion of PHT from the parathyroid glands could be useful in treating the various forms of hyperparathyroidism and/or osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nemeth EF 1990 Regulation of cytosolic calcium by extracellular divalent cations in C-cells and parathyroid cells. Cell Calcium 11:323–327

    Article  PubMed  CAS  Google Scholar 

  2. Brown EM, Butters R, Katz C, Kifor O 1991 Neomycin mimics the effects of high extracellular calcium concentrations on parathyroid function in dispersed bovine parathyroid cells. Endocrinology 128:3047–3054

    Article  PubMed  CAS  Google Scholar 

  3. Brown EM, Katz C, Butters R, Kifor O 1991 Polyarginine, polylysine, and protamine mimic the effects of high extracellular calcium concentrations on dispersed bovine parathyroid cells. J Bone Miner Res 6:1217–1225

    Article  PubMed  CAS  Google Scholar 

  4. Nemeth EF, Fox J 1999 Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol Metab 10:66–71

    Article  PubMed  CAS  Google Scholar 

  5. Nemeth EF, Bennett SA 1998 Tricking the parathyroid gland with novel calcimimetic agents. Nephrol Dial Transplant 13:1923–1925

    Article  PubMed  CAS  Google Scholar 

  6. Hammerland LG, Garrett JE, Hung BCP, Levinthal C, Nemeth EF 1998 Allosteric activation of the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol 53:1083–1088

    PubMed  CAS  Google Scholar 

  7. Conigrave AD, Quinn SJ, Brown EM 2000 L-Amino acid sensing by the extracellular Ca2+-sensing receptor. Proc Natl Acad Sci USA 97: 4814–4819

    Article  PubMed  CAS  Google Scholar 

  8. Hammerland LG, Garrett JE, Krapcho KJ, Simin R, Capuano IV, Alasti N, Nemeth EF, Fuller FH 1996 NPS R-467 activation of chimeric calcium-metabotrophic glutamate receptors and a calcium receptor deletion mutant indicates a site of action within the transmembrane domain of the calcium receptor. J Bone Miner Res 11: S158

    Google Scholar 

  9. Hauache OM, Hu J, Ray K, Xie R, Jacobson KA, Spiegel AM 2000 Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+-receptor and on a Ca2+-receptor/metabotropic glutamate chimeric receptors. Endocrinology 141:4156–4163

    Article  PubMed  CAS  Google Scholar 

  10. Fox J, Lowe SH, Petty BA, Nemeth EF 1999 NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J Pharmacol Exp Ther 290:473–479

    PubMed  CAS  Google Scholar 

  11. Lavigne JR, Zahradnik RJ, Conklin RL, Lambert LD, Logan MA, Parihar A, Fox J 1998 Stimulation of Calcitonin Secretion by Calcium Receptor Activators. Endocrine 9:293–301

    Article  PubMed  CAS  Google Scholar 

  12. Fox J, Lowe SH, Conklin RL, Petty BA, Nemeth EF 1999 Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca2+ receptor in rats. J Pharmacol Exp Ther 290:480–486

    PubMed  CAS  Google Scholar 

  13. Nemeth EF, DelMar EG, Heaton WL, Miller MA, Lambert LD, Conklin RL, Gowen M, Gleason JG, Bhatnagar PK, Fox J 2001 Calcilytic compunds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J Pharmacol Exptl Therap 299:323–331

    CAS  Google Scholar 

  14. Heath HIII 1991 Primary hyperparathyroidism: Recent advances in pathogenesis, diagnosis, and management. Adv Int Med 37: 275–293.

    Google Scholar 

  15. Fischer JA 1993 “Asymptomatic” and symptomatic primary hyperparathyroidism. Clin Invest 71:505–518

    CAS  Google Scholar 

  16. Bilezikian, JP 1994 Guidelines for the medical or surgical management of primary hyperparathyroidism. In: Bilezikian JP, Levine MA, Marcus R (ed) The Parathyroids. Raven Press Ltd., New York: 519–529

    Google Scholar 

  17. Clark OH 1995 Surgical treatment of primary hyperparathyroidism. Adv Endocrinol Metab 6:1–16

    PubMed  CAS  Google Scholar 

  18. Shane E, Bilezikian JP 1982 Parathyroid carcinoma: a review of 62 patients. Endocr Rev 3:218–226

    Article  PubMed  CAS  Google Scholar 

  19. Stock JL, Marcus R 1994 Medical management of primary hyperparathyroidism. In: Bilezikian JP, Levine MA, Marcus R (ed) The Parathyroids. Raven Press Ltd., New York: 519–529

    Google Scholar 

  20. Silverberg SJ, Bone HG III, Marriott TB, Locker FG, Thys-Jacobs S, Dziem G, Kaatz S, Sanguinetti EL, Bilezikian JP 1997 Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. New Engl J Med 337:1506–1510

    Article  PubMed  CAS  Google Scholar 

  21. Shoback DM, Bilezikian J, Binder TA, Graves T, Turner SA, Peacock M 2000 Calcimimetic AMG 073 normalizes total serum calcium in patients with primary hyperparathyroidism. J Bone Miner Res 15: S210

    Google Scholar 

  22. Shoback DM, Firek AF, Mims RB, Binder TA, Graves T, Turner SA, Peacock M 2001 The effect of the calcimimetic AMG 073 in patients with hypercalcemia and primary hyperparathyroidism (PHPT). J Bone Miner Res 16(suppl. 1):5303

    Google Scholar 

  23. Peacock M, Shoback DM, Greth WE, Binder TA, Graves T, Brenner RM, Turner SA, Marcus R 2001 The calcimimetic AMG 073 reduces serum calcium (Ca) in patients wit primary hyperparathyroidism (PHPT). J Bone Miner Res 16(suppl. 1):5163

    Google Scholar 

  24. Shane E 2001 Parathyroid carcinoma. In: Bilezikian JP, Marcus R, Levine, MA (ed) The Parathyroids. Academic Press, San Diego: 515–525

    Chapter  Google Scholar 

  25. Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ 1998 Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 83:1083–1088

    Article  PubMed  CAS  Google Scholar 

  26. Coburn JW, Salusky IB 1994 Hyperparathyroidism in renal failure. Clinical features, Diagnosis, and Management. In: Bilezikian JP, Levine MA, Marcus R (ed) The Parathyroids. Raven Press Ltd., New York: 519–529

    Google Scholar 

  27. Drüeke TB 1995 The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 48:259–272

    Article  PubMed  Google Scholar 

  28. Fajtova VT, Sayegh MH, Hickey N, Aliabadi P, Lazarus JM, LeBoff MS 1995 Intact parathyroid hormone levels in renal insufficiency. Calcif Tissue Int 57:329–335

    Article  PubMed  CAS  Google Scholar 

  29. Fournier A, Drueke T, Morinieagre P, Zingraff J, Boudailliez B, Achard JM 1992 The new treatments of hyperparathyroidism secondary to renal insufficiency. Adv Nephrol 21:237–306

    CAS  Google Scholar 

  30. Felsenfeld AJ 1997 Considerations for the treatment of secondary hyperparathyroidism in renal failure. J Am Soc Of Nephrol 7:993–1004

    Google Scholar 

  31. Herrmann P, Ritz E, Schmidt-Gayk H, Schaaufer I, Geyer J, Nonnast-Daniel B, Koch KM, Weber U, Hoaurl W, Haas-Woaurle A, Kuauhn K, Bierther B, Schneider P 1994 Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: A randomized prospective trial. Nephron 67:48–53

    Article  PubMed  CAS  Google Scholar 

  32. Mazzaferro S, Pasquali M, Ballanti P, Bonucci E, Di Sanza P, Sardella D, Taggi F, Coen G 1994 Intravenous versus oral calcitriol therapy in renal osteodystrophy: Results of a prospective, pulsed and dose-comparable study. Miner Electrolyte Metab 20:122–129

    PubMed  CAS  Google Scholar 

  33. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA 1994 Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 45:1710–1721

    Article  PubMed  CAS  Google Scholar 

  34. Korkor DA 1987 Reduced binding of 1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure. N Engl J Med 316: 1573–1577

    Article  PubMed  CAS  Google Scholar 

  35. Merke J, Huaugel U, Zlotkowski A, Szaboaa A, Bommer J, Mall G, Ritz E 1987. Diminished parathyroid 1,25(OH)2D3 receptors in experimental uremia. Kidney Int 32:350–353

    Article  PubMed  CAS  Google Scholar 

  36. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J 1998 19-Nor-la25 dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9:1427–1432

    PubMed  CAS  Google Scholar 

  37. Tan AU Jr., Levine BS, Mazess RB, Kyllo DM, Bishop CW, Knutson JC, Kleinman KS, Coburn JW 1997 Effective suppression of parathyroid hormone by la hydroxy vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 51: 317–323

    Article  PubMed  CAS  Google Scholar 

  38. Frazão JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW 2000 Intermittent doxercalciferol (1α-hydroxyvitamin D2) therapy for secondary hyperparathyroidism. Am J Kidney Dis 36:550–561

    Article  PubMed  Google Scholar 

  39. Mathias RS, Nguyen HT, Zhang MYH, Portale AA 1998 Reduced expression of the renal calcium-sensing receptor in rats with experimental chronic renal insufficiency. J Am Soc Nephrol 9:2067–2074

    PubMed  CAS  Google Scholar 

  40. Brown AJ, Ritter CS, Finch JL, Slatopolsky EA 1999 Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. Kidney Int 55:1284–1292

    Article  PubMed  CAS  Google Scholar 

  41. Fox J, Conklin RL, Lambert LD, Nemeth EF 2000 The potency of the calcimimetic NPS R-568 is unaffected in rats with severe secondary hyperparathyroidism. J Am Soc Nephrol 11:575A

    Google Scholar 

  42. Fox J, Conklin RL, Lambert LD, Nemeth EF 2000 The potency of the calcimimetic NPS R-568 is unaffected in rats with severe secondary hyperparathyroidism. J Am Soc Nephrol 11:575A

    Google Scholar 

  43. Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N 1998 NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 53: 448–453

    Article  PubMed  CAS  Google Scholar 

  44. Naveh-Many T, Rahamimov R, Livni N, Silver J 1995 Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitmamin D. J Clin Invest 96:1786–1793

    Article  PubMed  CAS  Google Scholar 

  45. Wernerson A, Widholm SM, Svensson O, Reinholt FP 1991 Parathyroid cell number and size in hypocalcemic young rats. APMIS 99:1096–1102

    Article  PubMed  CAS  Google Scholar 

  46. Denda M, Finch J, Slatopolsky E 1996 Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 28:596–602

    Article  PubMed  CAS  Google Scholar 

  47. Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, Nagano N 1997 The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insuffiency: control of parathyroid cell growth via a calcium receptor. J Clin Invest 100:2977–2983

    Article  PubMed  CAS  Google Scholar 

  48. Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, Fox J 2000 Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 57: 50–58

    Article  PubMed  CAS  Google Scholar 

  49. Chin J, Miller SC, Michihito W, Nagano N, Nemeth EF, Fox J 2000 Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol 11:903–911

    PubMed  CAS  Google Scholar 

  50. Antonsen JE, Sherrard DJ, Andress DL 1998 A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int 53:223–227

    Article  PubMed  CAS  Google Scholar 

  51. Akizawa T, Suzuki M, Tominaga Y, Saito A, Uchida E, Kawaguchi Y, Ogata E, Kurokawa, K 1998 Acute effect of calcimimetic agent (CA) on hemodialysis (HD) patients with secondary hyperpara-thyroidism (2HPT). J Am Soc Nephrol 9:561A

    Google Scholar 

  52. Antonsen JE, Sherrard DJ, Andress DL 1998 A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int 53:223–227

    Article  PubMed  CAS  Google Scholar 

  53. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW 2000 A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58:436–445

    Article  PubMed  CAS  Google Scholar 

  54. Coburn JW, Barri YM, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Goodman WG 2000 Single doses of the calcimimetic AMG 073 reduce parathyroid hormone levels in a dose dependent manner in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 11: 73A–574A

    Google Scholar 

  55. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Cohen RM, Coburn JW 2000 Multiple doses of the calcimimetic AMG073 reduce plasma parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism (SHPT). J Am Soc Nephrol 11:576A

    Google Scholar 

  56. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Turner SA, Blaisdell PW, McCary LC, Brenner RM, Liu W, Martin KJ 2000 The calcimimetic AMG 073 reduces parathyroid hormone (PTH), phosphorus, and calcium x phosphorus product (Ca x P) in patients with ESRD and secondary hyperparathyroidism. J Am Soc Nephrol 11:578A

    Google Scholar 

  57. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Brenner RM, Liu W, Turner SA, Bushinsky DA 2001 The calcimimetic AMG 073 reduces PHT and Ca x P in patients with secondary hyperparathyroidism (SHPT). J Am Soc Nephrol 12:771A

    Google Scholar 

  58. Driieke T, Cunningham J, Goodman WG, Hörl WH, Braun J, Chen M-G, McCary LC, Steinhauslin-Jeanrenaud F, Turner SA, Ritz E 2001 Short-term treatment of secondary hyperparathyroidism (SHPT) with the calcimimetic agent AMG 073. J Am Soc Nephrol 12:764A

    Google Scholar 

  59. Naveh-Many T, Silver J 1990 Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J Clin Invest 86:1313–1319

    Article  PubMed  CAS  Google Scholar 

  60. Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Secre GV, Salusky IB 1994 Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:1160–1166

    Article  PubMed  CAS  Google Scholar 

  61. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV 1993 The spectrum of bone disease in end-stage renal failure an evolving disorder. Kidney Int 43: 436–442

    Article  PubMed  CAS  Google Scholar 

  62. Schmitt CP, Hessing S, Oh J, Weber L, Ochlich P, Mehls O 2000 Intermittent administration of parathyroid hormone (1-37) improves growth and bone mineral density in uremic rats. Kidney Int 57:1484–1492

    Article  PubMed  CAS  Google Scholar 

  63. Ishii H, Wada M, Furuya Y, Nagano N, Nemeth EF, Fox J 2000 Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 26:175–182

    Article  PubMed  CAS  Google Scholar 

  64. Antonsen JE, Sherrard DJ 1995 Renal osteodystrophy: past and present. Semin Dial 9:296–302

    Article  Google Scholar 

  65. Silverberg SJ, Gartenberg F, Jacobs TP, Shane E, Siris E, Staron RB, McMahon DJ, Bilezekian JP 1995 Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab 80:729–734

    Article  PubMed  CAS  Google Scholar 

  66. Mosekilde L, Søgaard CH, Danielsen CC, Tørring O, Nilsson MHL 1991 The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also refelcted in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(l-34) and hPTH-(l-84). Endocrinology 129:421–428

    Article  PubMed  CAS  Google Scholar 

  67. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R 1993 Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690–709

    PubMed  CAS  Google Scholar 

  68. Kimmel DB, Bozzato RP, Kronis KA, Coble T, Sindrey D, Kwong P, Recker RR 1993 The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult ovariectomized rats. Endocrinology 132:1577–1584

    Article  PubMed  CAS  Google Scholar 

  69. Li M, Wronski TJ 1995 Response of femoral neck to estrogen depletion and parathyroid hormone in aged rats. Bone 16: 551–557

    Article  PubMed  CAS  Google Scholar 

  70. Ejersted C, Andreassen TT, Hauge EM, Melson F, Oxlund H 1995 Parathyroid hormone (1-34) increases vertebral bone mass, compressive strength, and quality in old rats. Bone 17:507–511

    Article  PubMed  CAS  Google Scholar 

  71. Fox J, Miller MA, Stroup GB, Nemeth EF, Miller SC 1997 Plasma levels of parathyroid hormone that induce anabolic effects in bone ovariectomized rats can be achieved by stimulation of endogenous hormone secretion. Bone 21:163–169

    Article  PubMed  CAS  Google Scholar 

  72. Reeve J 1996 PTH: a future role in the management of osteoporosis? J Bone Miner Res 11:440–445

    Article  PubMed  CAS  Google Scholar 

  73. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis. Lancet 350:550–555

    Article  PubMed  CAS  Google Scholar 

  74. Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D 1997 A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 82: 620–628

    Article  PubMed  CAS  Google Scholar 

  75. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 102:1627–1633

    Article  PubMed  CAS  Google Scholar 

  76. Fujita T, Inoue T, Morii H, Norimatsu H, Orimo H, Takahashi HE, Yamamoto K, Fukunaga M 1999 Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels. Osteporosis Int 9:296–306

    Article  CAS  Google Scholar 

  77. Rittmaster RS, Bolognese M., Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129–2134

    Article  PubMed  CAS  Google Scholar 

  78. Mosekilde L, Sogaard CH, McOsker JE, Wronski TJ 1994 PHT has a more pronounced effect on vertebral bone mass and biomechanical competence than antiresorptive agents (estrogen and bisphosphonate)-assessed in sexually mature, ovariectomized rats. Bone 15:401–408

    Article  PubMed  CAS  Google Scholar 

  79. Sogaard CH, Wronski TJ, McOsker JE, Moselkilde L 1994 The positive effect of parathyroid hormone on femoral neck bone strength in ovariectomized rats is more pronounced than that of estrogen or bisphosphonates. Endocrinology 134:650–657

    Article  PubMed  CAS  Google Scholar 

  80. Nemeth EF 1996 Calcium Receptors as Novel Drug Targets. Principles of Bone Biology Chapter 73:1019–1035

    Google Scholar 

  81. Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, Bhatnagar PK, Lago AM, Callahan JF, DelMar EG, Miller MA, Nemeth EF, Fox J 2000 Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 105:1595–1604

    Article  PubMed  CAS  Google Scholar 

  82. Ham AW, Littner BA, Drake TGH, Robertson EC, Tisdall FF 1940 Physiological hypertrophy of the parathyroids, its cause and its relation to rickets. Am J Pathol 15:277–286

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. NPS Pharmaceuticals, Inc., 30 College Street / Suite 301, Toronto, Ontario, M5G 1K2, Canada

    Edward F. Nemeth Ph.D. & John Fox Ph.D.

Authors
  1. Edward F. Nemeth Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Fox Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Endocrine-Hypertension Division Department of Medicine, Brigham and Women’s Hospital Harvard Medical School, Boston, Massachusetts, USA

    Naibedya Chattopadhyay  & Edward M. Brown  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Nemeth, E.F., Fox, J. (2003). Compounds Acting on the Parathyroid Calcium Receptor as Novel Therapies for Hyperparathyroidism or Osteoporosis. In: Chattopadhyay, N., Brown, E.M. (eds) Calcium-Sensing Receptor. Endocrine updates, vol 19. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9256-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-9256-7_8

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-4861-0

  • Online ISBN: 978-1-4419-9256-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation